A new once daily triple drug treatment for cystic fibrosis is set to be “immediately funded” by NHS England following recommendation from the National Institute for Health and Care Excellence (NICE).1 ...

BETHESDA, Md. (July 16, 2025) – Today, the Cystic Fibrosis Foundation announced an additional investment of up to $24 million ...

Axtell spent 15 hours paddleboarding the gap between Bimini and Lake Worth Beach. Although stormy and hot weather made it ...

NHS patients in England with cystic fibrosis will be among the first in Europe to access a new treatment for their condition, ...

Reimbursement authority NICE has backed routine NHS use of Vertex's once-daily triple therapy Alyftrek ...

Charles Kim Haskell told Newsweek he once thought he wouldn't live beyond his teenage years, but, at 31, he is enjoying his life.

BiomX has dosed the first subject in the randomised Phase IIb trial of the company’s fixed multi-phage therapy, BX004, to ...

It said that 95% of people with cystic fibrosis in England will now be eligible for modulator therapy. The new drug, also ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of Goldman Sachs’ top healthcare stock picks. On July 1, the ...

Expanded funding builds on the initial agreement to accelerate development of Prime Editors for Cystic Fibrosis (CF) -- -- Prime Medicin ...

Vertex Pharmaceuticals (VRTX) experienced a 4% price increase over the past month, coinciding with crucial developments in their portfolio. The recent advancement with NHS England's reimbursement ...

NHS England » NHS to roll-out new ‘triple combination’ therapy for hundreds of children and adults with cystic fibrosis ...